This case explores the challenges faced by developing countries, where HIV is widely prevalent, in providing their citizens access to HIV medications. Supplying consistent treatments of Antiretroviral Therapy (ART) medications continue to be an obstacle due to its high costs in relation to individual income and government health budgets, and the strict patent laws governing them when attempting to domestically produce generics at a much lower price. Other barriers such as lack of medical facilities, outlay of tests and availability of clinics, coupled with the social stigma of HIV and AIDS, prevent persons infected to seek treatment.